Cancer Therapy

Sicor announces tentative ANDA approval for carboplatin injection

Published in Women's Health Weekly, October 3rd, 2002

Sicor Inc., (SCRI) announced that the Food and Drug Administration (FDA) has tentatively approved an abbreviated new drug application (ANDA) by its wholly owned subsidiary, Gensia Sicor Pharmaceuticals, Inc., for Carboplatin Injection.

Carboplatin is indicated for the treatment of patients with ovarian cancer. Gensia Sicor's carboplatin product is a liquid ready-to-use formulation packaged in a shatter resistant polymer vial.

Based on data from IMS Health, a market research firm, U.S. sales of carboplatin in 2001 were approximately $470 million. The branded product, Paraplatin, is marketed by Bristol-Myers Squibb.

Sicor, Inc.,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2002-10-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry